Pharmacovigilance and Safety Assessment

Pharmacovigilance and safety assessment are critical components of drug development and post-market surveillance, ensuring the safety and efficacy of pharmaceutical products. Pharmacovigilance involves the monitoring, detection, assessment, and prevention of adverse drug reactions (ADRs) or other drug-related problems. Safety assessments include preclinical and clinical trials, where potential risks are evaluated in controlled environments, followed by real-world monitoring once the drug is marketed. This ongoing process helps identify rare or long-term side effects and ensures that the benefits of a drug continue to outweigh the risks. Effective pharmacovigilance promotes public health and regulatory compliance, supporting patient safety across diverse therapeutic areas.

 

    Related Conference of Pharmacovigilance and Safety Assessment

    November 22-23, 2024

    4th International Conference on Medical Research and Development

    Aix-en-Provence, France
    November 25-26, 2024

    10th World Congress on Anesthesia and Critical Care

    Paris, France
    May 12-13, 2025

    19th International Conference on Obesity Medicine

    Toronto, Canada
    June 24-25, 2025

    3rd Global Summit on HIV-AIDS and STDs

    Chicago, USA
    July 16-17, 2025

    11th World Congress on Medicinal Plants and Marine Drugs

    Aix-en-Provence, France
    August 07-08, 2025

    12th World Summit on Epilepsy and Bipolar Disorders

    Paris, France

    Pharmacovigilance and Safety Assessment Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in